FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893060276> ?p ?o ?g. }

• W2893060276 endingPage "94" @default.
• W2893060276 startingPage "84" @default.
• W2893060276 abstract "Human cytomegalovirus (HCMV) is a major human pathogen with seropositivity rates in the adult population ranging between 40% and 95%. HCMV infection is associated with severe pathology, such as life-threatening courses of infection in immunocompromised individuals and neonates. Current standard therapy with valganciclovir has the disadvantage of adverse side effects and viral drug resistance. A novel anti-HCMV drug, letermovir, has been approved recently, so that improved therapy options are available. Nevertheless, even more so far unexploited classes of compounds and molecular modes of action will be required for a next generation of antiherpesviral treatment strategies. In this study, we focused on the analysis of the antiviral potency of a novel class of compounds, i.e. pyrrolopyridine analogs, and identified both hit compounds and their target protein candidates. In essence, we provide novel evidence as follows: (i) screening hit SC88941 is highly active in inhibiting HCMV replication in primary human fibroblasts with an EC50 value of 0.20 ± 0.01 μM in the absence of cytotoxicity, (ii) inhibition occurs at the early-late stage of viral protein production and shows reinforcing effects upon LMV cotreatment, (iii) among the viruses analyzed, antiviral activity was most pronounced against β-herpesviruses (HCMV, HHV-6A) and intermediate against adenovirus (HAdV-2), (iv) induction of SC88941 resistance was not detectable, thus differed from the induction of ganciclovir resistance, (v) a linker-coupled model compound was used for mass spectrometry-based target identification, thus yielding several drug-binding target proteins and (vi) a first confocal imaging approach used for addressing intracellular effects of SC88941 indicated qualitative and quantitative alteration of viral protein expression and localization. Thus, our findings suggest a multifaceted pattern of compound-target binding in connection with an unusual mode of action, opening up further opportunities of antiviral drug development." @default.
• W2893060276 created "2018-10-05" @default.
• W2893060276 creator A5022512574 @default.
• W2893060276 creator A5040808433 @default.
• W2893060276 creator A5043335832 @default.
• W2893060276 creator A5046466492 @default.
• W2893060276 creator A5046623192 @default.
• W2893060276 creator A5052002848 @default.
• W2893060276 creator A5052967645 @default.
• W2893060276 creator A5055719334 @default.
• W2893060276 creator A5057324599 @default.
• W2893060276 creator A5068913705 @default.
• W2893060276 creator A5068957488 @default.
• W2893060276 creator A5072322511 @default.
• W2893060276 creator A5075525711 @default.
• W2893060276 creator A5085954072 @default.
• W2893060276 creator A5089773178 @default.
• W2893060276 date "2018-11-01" @default.
• W2893060276 modified "2023-10-14" @default.
• W2893060276 title "Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity" @default.
• W2893060276 cites W1987560539 @default.
• W2893060276 cites W2014582878 @default.
• W2893060276 cites W2024993627 @default.
• W2893060276 cites W2032395580 @default.
• W2893060276 cites W2035982103 @default.
• W2893060276 cites W2044936417 @default.
• W2893060276 cites W2046433603 @default.
• W2893060276 cites W2060917730 @default.
• W2893060276 cites W2077185287 @default.
• W2893060276 cites W2078353937 @default.
• W2893060276 cites W2096451853 @default.
• W2893060276 cites W2101396334 @default.
• W2893060276 cites W2108928565 @default.
• W2893060276 cites W2109177153 @default.
• W2893060276 cites W2118279792 @default.
• W2893060276 cites W2123344591 @default.
• W2893060276 cites W2126942314 @default.
• W2893060276 cites W2130220157 @default.
• W2893060276 cites W2138240302 @default.
• W2893060276 cites W2147902854 @default.
• W2893060276 cites W2148627084 @default.
• W2893060276 cites W2154662193 @default.
• W2893060276 cites W2158973497 @default.
• W2893060276 cites W2159702641 @default.
• W2893060276 cites W2165903332 @default.
• W2893060276 cites W2191485687 @default.
• W2893060276 cites W2202885949 @default.
• W2893060276 cites W2319680233 @default.
• W2893060276 cites W2511058007 @default.
• W2893060276 cites W2562224769 @default.
• W2893060276 cites W2593104383 @default.
• W2893060276 cites W2764242421 @default.
• W2893060276 doi "https://doi.org/10.1016/j.antiviral.2018.09.012" @default.
• W2893060276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30268914" @default.
• W2893060276 hasPublicationYear "2018" @default.
• W2893060276 type Work @default.
• W2893060276 sameAs 2893060276 @default.
• W2893060276 citedByCount "15" @default.
• W2893060276 countsByYear W28930602762019 @default.
• W2893060276 countsByYear W28930602762020 @default.
• W2893060276 countsByYear W28930602762021 @default.
• W2893060276 countsByYear W28930602762022 @default.
• W2893060276 countsByYear W28930602762023 @default.
• W2893060276 crossrefType "journal-article" @default.
• W2893060276 hasAuthorship W2893060276A5022512574 @default.
• W2893060276 hasAuthorship W2893060276A5040808433 @default.
• W2893060276 hasAuthorship W2893060276A5043335832 @default.
• W2893060276 hasAuthorship W2893060276A5046466492 @default.
• W2893060276 hasAuthorship W2893060276A5046623192 @default.
• W2893060276 hasAuthorship W2893060276A5052002848 @default.
• W2893060276 hasAuthorship W2893060276A5052967645 @default.
• W2893060276 hasAuthorship W2893060276A5055719334 @default.
• W2893060276 hasAuthorship W2893060276A5057324599 @default.
• W2893060276 hasAuthorship W2893060276A5068913705 @default.
• W2893060276 hasAuthorship W2893060276A5068957488 @default.
• W2893060276 hasAuthorship W2893060276A5072322511 @default.
• W2893060276 hasAuthorship W2893060276A5075525711 @default.
• W2893060276 hasAuthorship W2893060276A5085954072 @default.
• W2893060276 hasAuthorship W2893060276A5089773178 @default.
• W2893060276 hasConcept C114851261 @default.
• W2893060276 hasConcept C140704245 @default.
• W2893060276 hasConcept C159047783 @default.
• W2893060276 hasConcept C202751555 @default.
• W2893060276 hasConcept C2522874641 @default.
• W2893060276 hasConcept C2776120743 @default.
• W2893060276 hasConcept C2776409557 @default.
• W2893060276 hasConcept C2776724271 @default.
• W2893060276 hasConcept C2777732132 @default.
• W2893060276 hasConcept C2777965375 @default.
• W2893060276 hasConcept C2779756493 @default.
• W2893060276 hasConcept C2779820661 @default.
• W2893060276 hasConcept C2780727368 @default.
• W2893060276 hasConcept C2908647359 @default.
• W2893060276 hasConcept C55493867 @default.
• W2893060276 hasConcept C71924100 @default.
• W2893060276 hasConcept C86803240 @default.
• W2893060276 hasConcept C89423630 @default.
• W2893060276 hasConcept C98274493 @default.

• next